A Pilot Study of the Treatment of Facial Nodular and Nodulocystic Basal Cell Carcinoma With Double Curettage and Cautery Followed by Application of Imiquimod to the Base

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine recurrence rates of nodular Basal Cell Carcinomas on the face removed with curettage and electrodessication (cautery) followed by application of Imiquimod cream to the base and further to achieve lower recurrence rates than after treatment with curettage and electrodessication alone.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Glasgow
• Collaborators: Glasgow Western Infirmary; NHS Greater Glasgow and Clyde
• Treatments: Imiquimod

Criteria

Inclusion Criteria:

• Well-defined primary, not previously treated nodulo-cystic BCC

• Size of the lesions: ≤ 1cm diameter

• Facial lesions

• Patient compliance competent

• Patient physically able to apply the treatment (cream)

Exclusion Criteria:

• Recurrent lesions

• Superficial, morphoeic or pigmented BCC

• Lesions close to vital structures; i.e. where C&C is not considered a standard treatment (eyelids, inner canthus, free borders)

• Lesions within 1 cm of the eyelids, nose, lips and hairline

• Immunosuppressed patients

• Women in childbearing age, pregnancy and breast-feeding

• Ages <50 or >90

• Patients compliance incompetent

• Patients physically incapable to apply the treatment (cream)

• Patients with Gorlin Syndrome (nevoid Basal Cell Carcinoma syndrome)